EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting cardiometabolic risk in type 1 diabetes through incretin physiology

Ruth Frampton, Samantha Hocking, Jennifer R Snaith, Jerry R Greenfield

Trends in Endocrinology & Metabolism · 2026

DOI: 10.1016/j.tem.2025.06.004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Endocrinology & Metabolism, 2026. Verfasst von Ruth Frampton und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Diabetes and Metabolism, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia; St Vincent's Healthcare Clinical Ca…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Incretins, Cardiovascular Diseases. Die Arbeit nennt 91 Literaturangaben. Gefördert von: University of New South Wales, Medical Research Future Fund, Juvenile Diabetes Research Foundation Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1IncretinsCardiovascular DiseasesHumansGlucagon-Like Peptide 1AnimalsGastric Inhibitory PolypeptideInsulin Resistance

Stichwörter der Autor:innen

GIPGLP-1adjunctive therapiescardiovascular riskglucagontype 1 diabetes

Substanzen

IncretinsGlucagon-Like Peptide 1Gastric Inhibitory Polypeptide

Autor:innen und Institutionen

  • Clinical Diabetes and Metabolism, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia; St Vincent's Healthcare Clinical Campus, School of Clinical Medicine, University of New South Wales Medic…
  • Boden Initiative, Charles Perkins Centre, The University of Sydney, NSW, Australia; Central Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Department of Endocr…

Förderung

  • University of New South Wales
  • Medical Research Future Fund
  • Juvenile Diabetes Research Foundation Australia

Zitieren

APA

Frampton, R., Hocking, S., Snaith, J. R., & Greenfield, J. R. (2026). Targeting cardiometabolic risk in type 1 diabetes through incretin physiology. Trends in Endocrinology & Metabolism. https://doi.org/10.1016/j.tem.2025.06.004

Vancouver

Frampton R, Hocking S, Snaith JR, Greenfield JR. Targeting cardiometabolic risk in type 1 diabetes through incretin physiology. Trends in Endocrinology & Metabolism. 2026. doi:10.1016/j.tem.2025.06.004

BibTeX
@article{Frampton2026,
  author = {Frampton, Ruth and Hocking, Samantha and Snaith, Jennifer R and Greenfield, Jerry R},
  title = {Targeting cardiometabolic risk in type 1 diabetes through incretin physiology},
  journal = {Trends in Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1016/j.tem.2025.06.004}
}
Kostenlos starten →